(E)-1-(4-methoxybenzyl)-N'-(5-bromo-2-oxoindolin-3-ylidene)-1H-1,2,3-triazole-4-carbohydrazide

ID: ALA4461598

PubChem CID: 155528559

Max Phase: Preclinical

Molecular Formula: C19H15BrN6O3

Molecular Weight: 455.27

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  COc1ccc(Cn2cc(C(=O)N/N=C3/C(=O)Nc4ccc(Br)cc43)nn2)cc1

Standard InChI:  InChI=1S/C19H15BrN6O3/c1-29-13-5-2-11(3-6-13)9-26-10-16(22-25-26)18(27)24-23-17-14-8-12(20)4-7-15(14)21-19(17)28/h2-8,10H,9H2,1H3,(H,24,27)(H,21,23,28)

Standard InChI Key:  XRQIAUMOJYKBNO-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 29 32  0  0  0  0  0  0  0  0999 V2000
   40.1916  -11.6848    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   39.9373  -10.9040    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.1201  -10.9040    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.5287  -12.1627    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.8702  -11.6831    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.1277  -12.0136    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.0425  -12.8235    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.7058  -13.3018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.4456  -12.9686    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   40.4174  -10.2427    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   38.6385  -10.2438    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   32.4386   -9.2821    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.4375  -10.1058    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.1496  -10.5189    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.8593  -10.1053    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.8565   -9.2785    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.1478   -8.8732    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.7253  -10.5179    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   31.0138  -10.1046    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.5667   -8.8672    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.2801   -9.2732    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   35.3723  -10.0886    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   36.1764  -10.2555    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   36.5864   -9.5421    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.0331   -8.9370    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.4051   -9.5380    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.8172  -10.2478    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   37.8101   -8.8283    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   37.2965  -13.1572    0.0000 Br  0  0  0  0  0  0  0  0  0  0  0  0
  3  5  1  0
  1  2  1  0
  4  1  1  0
  2  3  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9  4  1  0
  2 10  2  0
  3 11  2  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 12  1  0
 13 18  1  0
 18 19  1  0
 16 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 21  1  0
 24 26  1  0
 26 27  1  0
 26 28  2  0
 27 11  1  0
  7 29  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4461598

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 455.27

Molecular Weight (Monoisotopic): 454.0389

AlogP: 2.18

#Rotatable Bonds: 5

Polar Surface Area: 110.50

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 8.59

CX Basic pKa: ┄

CX LogP: 3.00

CX LogD: 2.97

Aromatic Rings: 3

Heavy Atoms: 29

QED Weighted: 0.57

Np Likeness Score: -1.87

References

1. Aneja B, Khan NS, Khan P, Queen A, Hussain A, Rehman MT, Alajmi MF, El-Seedi HR, Ali S, Hassan MI, Abid M..  (2019)  Design and development of Isatin-triazole hydrazones as potential inhibitors of microtubule affinity-regulating kinase 4 for the therapeutic management of cell proliferation and metastasis.,  163  [PMID:30579124] [10.1016/j.ejmech.2018.12.026]

2. Klaeger, Susan S and 47 more authors.  2017-12-01  The target landscape of clinical kinase drugs.  [PMID:29191878]

3. Narayan, Satya S and 7 more authors.  2019-01-01  ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.  [PMID:30384048]

Source

Source(1):

• Scientific Literature